Edition:
United States

Applied Genetic Technologies Corp (AGTC.OQ)

AGTC.OQ on NASDAQ Stock Exchange Global Market

5.00USD
20 Apr 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$5.00
Open
$5.05
Day's High
$5.05
Day's Low
$5.00
Volume
3,570
Avg. Vol
19,509
52-wk High
$6.40
52-wk Low
$3.28

Chart for

About

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of... (more)

Overall

Beta: 2.18
Market Cap(Mil.): $90.52
Shares Outstanding(Mil.): 18.10
Dividend: --
Yield (%): --

Financials

  AGTC.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -0.70 -- --
ROI: -10.78 -0.74 13.19
ROE: -11.05 -2.80 15.00

BRIEF-AGTC Doses First Patient In Phase 1/2 Clinical Study Of Gene Therapy For Treatment Of X-Linked Retinitis Pigmentosa

* AGTC DOSES FIRST PATIENT IN PHASE 1/2 CLINICAL STUDY OF GENE THERAPY FOR TREATMENT OF X-LINKED RETINITIS PIGMENTOSA Source text for Eikon: Further company coverage:

Apr 18 2018

BRIEF-Applied Genetic Technologies Reports Quarterly Loss Per Share Of ‍$ 0.29​

* ‍APPLIED GENETIC TECHNOLOGIES QTRLY REVENUE $4.9 MILLION VERSUS $10.9 MILLION

Feb 09 2018

BRIEF-Applied Genetic Technologies Reports Qtrly Loss Per Share Of ‍$0.29​

* ‍AS OF DECEMBER 31, 2017, COMPANY'S CASH, CASH EQUIVALENTS, AND INVESTMENTS AMOUNTED TO $119.7 MILLION​

Feb 09 2018

BRIEF-Applied Genetic posts qtrly ‍net loss of $0.08​ per share

* Company expects total cash, cash equivalents, and investments as of june 30, 2018 to be between $85 and $100 million​

Nov 07 2017

Earnings vs. Estimates